BLSM
BlossomHill Therapeutics, Inc.(BLSM)解禁日期与限售安排
IPO 禁售期到期
禁售期到期 / 解禁日期103 天后市场日期参考时区:America/New_York。具体解禁时点以原文为准。
预计日期 · 来源已核验原始披露与证据
来源披露的预计日期,仍可能根据后续文件调整。
证据阅读提示
以下按日期、股份或限制相关词定位已保存证据摘要片段。摘要不等同于原始文件逐字引文,也不构成独立核验结论;完整条款以原始文件为准。
- 证据中的日期
- Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BLSM The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
展开已保存的完整证据摘要
Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BLSM The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitt
he market price of our common stock to drop significantly, even if our business is doing well. Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares of our common stock, could reduce the market price of our common stock. In connection with our IPO, our directors and executive officers and substantially all of our pre-IPO securityholders entered into lock-up agreements with the representatives of the underwriters pursuant to which they may not, with limited exceptions, through February 2, 2027, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of the representatives of the underwriters. The underwriters may permit our officers, directors and other securityholders who are subject to the lock-up agreements to sell shares prior to the expiration of the lock-up agreements at any time in their sole discretion. Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the lock-up agreements expire, these shares of common stock will be eligible for sale in the public market, except that shares held by directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended (Securities Act). Moreover, certain holders of shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Rule 144 under the Securities Act, or until the rights terminate pursuant to the terms of the stockholder agreements between us and such holders. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. We also registered all shares of our comm- 证据核验时间
- 2026年10月20日 08:36
- 更新时间
- 2026年10月20日 08:36
本记录的披露范围
这里记录的是来源披露的股份限制或可售窗口。日期核验与股数核验相互独立;日期到来不等于股东已出售,也不代表你的账户已获准交易。
日期状态:来源中的预计安排。即使日期已经过去,也不自动认定已经完成。
仍需核对的事项
- 本记录尚未核验可解禁股数,不能用 IPO 发行股数替代。
- 尚未核验流通股本影响;占比需要注明日期、股份类别口径一致的流通股本基数。
- 具体解禁时点与时区、适用股东、提前解除禁售的条件及券商办理要求,仍需逐项核对适用文件。